ArticleGastroenterology2012
Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.
Josh Levitsky et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this papercites it